An experimental flu vaccine consisting of billions of tiny spherical sacs that carry infection-fighting proteins throughout the body is effective in preclinical studies, according to new research.
Described in a study in the Proceedings of the National Academy of Sciences, the vaccine has the potential to:
- Improve the effectiveness of seasonal flu vaccines, which typically work 40-60% of the time, according to the US Centers for Disease Control and Prevention.
- Take less time to produce large quantities because, unlike most seasonal flu vaccines, it is not created in embryonated chicken eggs.
- Use smaller doses—and increase vaccine supplies—which can be critical given the unpredictable nature of influenza.
“The results are very encouraging,” says study senior coauthor, Jonathan Lovell, associate professor of biomedical engineering at the University at Buffalo.
“Typically, flu vaccines contain either deactivated microbes that cause influenza, or they are based on weakened forms of the disease. The vaccine we’re developing is a recombinant protein nanoparticle vaccine that stimulates a strong immune response.”
Key to the vaccine’s success is a liposome Lovell and colleagues created called cobalt-porphyrin-phospholipid, or CoPoP.
These tiny spherical sacs, which are small enough to be considered nanoparticles, form the backbone of what is known pharmaceutical parlance as a vaccine platform, which is any underlying technology used to develop multiple vaccines.
Alone, these liposomes don’t fight disease. But they possess a special talent. They spontaneously convert virus proteins that prompt immune responses into a more potent nanoparticle format.
“This conversion is advantageous because the dissolved proteins attach to the surface of the liposomes, where the proteins enhance the immune system’s response to disease,” says senior author Matthew Miller, associate professor of biochemistry and biomedical sciences at McMaster University.
“The dose-sparing effect is important because it means we could create many more doses using less materials.”
For the study, the researchers introduced a group of proteins known as hemagglutinin to the CoPop liposomes. One particular hemagglutinin, known as trimeric H3 HA, triggered a strong immune response in mice.
“The nanoparticles carry the trimeric H3 HA to the body’s immune cells, and they provoke those immune cells to respond more vigorously to the flu,” says lead author Zachary Sia, a PhD candidate in Lovell’s lab.
In experiments involving flu virus strain H3N2, the researchers injected blood serum from vaccinated mice into non-vaccinated mice. The injection provided protection against H3N2. In experiments with ferrets involving a more modern H3N2 strain, the vaccine reduced the amount of virus in the animals’ upper respiratory system.
Even with doses as low as 2 nanograms, the vaccine provided a similar level of protection that vaccines with doses typically measured in micrograms, or roughly 1,000 times more.
“The dose-sparing effect is important because it means we could create many more doses using less materials.” says senior coauthor Bruce Davidson, research associate professor of anesthesiology in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo. “Simply put, CoPoP likely will provide greater immune protection with less hemagglutinin than current vaccines.”
The vaccine platform is also versatile.
Researchers could simultaneously bind 10 recombinant proteins representing distinct influenza virus strains to generate a highly multivalent nanoparticle. A 5 nanogram dose in mice offered protection against the H5N1 flu strain, more commonly known as bird flu, a virus that epidemiologists say has the potential to trigger a pandemic.
While not part of this study, researchers are using the platform in clinical trials in South Korea as a COVID-19 vaccine candidate. This is a partnership between the University at Buffalo spinoff company POP Biotechnologies, which Lovell and South Korean biotech company EuBiologics cofounded. POP Biotechnologies is also working with Scripps Research to study the platform in a possible HIV vaccine.
The National Institutes of Health, a Canadian Institutes of Health Research (CIHR) New Investigator Award from the Government of Ontario, a Physicians Services Inc. Research Trainee Fellowship, and a CIHR Canada Graduate Scholarship funded the current study.
The Veterans Affairs Western New York Healthcare System, the Facility for Electron Microscopy Research at McGill University, and the Canadian Foundation for Innovation and the Government of Quebec provided additional support.
Lovell and coauthor Wei-Chiao Huang hold interest in POP Biotechnologies.
Source: University of Buffalo
